Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

Trial Profile

A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plinabulin (Primary) ; Docetaxel; Pegfilgrastim
  • Indications Neutropenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Protective-1
  • Sponsors BeyondSpring Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2023 Pooled analysis of NCT02504489; NCT03102606; NCT00630110 trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 13 Dec 2022 According to BeyondSpring Pharmaceuticals media release, data of this study was presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) and at ESMO Asia Congress 2022.
    • 13 Sep 2022 Results by obtaining data from PROTECTIVE-1 and PROTECTIVE-2, evaluating plins protective effects on granulocyte-monocyte progenitor , presented at the 47th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top